Trial Profile
A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Metformin (Primary) ; SAR 425899 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 01 Aug 2021 Primary endpoint (Change From Baseline in HbA1c to Week 26) has been met, according to Results published in the Diabetes, Obesity and Metabolism.
- 01 Aug 2021 Results published in the Diabetes, Obesity and Metabolism.
- 08 Jan 2018 Status changed from active, no longer recruiting to completed.